Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01644656 · ClinicalTrials.gov registry record · NA

Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)

A NA study of Portal Hypertension and Chronic Liver Disease, sponsored by VA Connecticut Healthcare System.

Completed
Registry status
NA
Development phase
500
Enrollment target
2
Study locations

NCT01644656: Completed NA study of Portal Hypertension and Chronic Liver Disease, sponsored by VA Connecticut Healthcare System.

NCT01644656 is a NA study of Portal Hypertension and Chronic Liver Disease that has completed, run by VA Connecticut Healthcare System. The registered enrollment target is 500 participants, above the 153-participant average among 9 other Portal Hypertension trials with a reported enrollment target (227% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01644656, a NA study of Portal Hypertension and Chronic Liver Disease, has completed, sponsored by VA Connecticut Healthcare System.

COMPLETED
Registry status
NA
Development phase
500 participants
Enrollment target
2
Study locations

Study Summary

The aim of this diagnostic study is to evaluate the efficacy of ARFI imaging (a specific type of ultrasound) in assessing the pressure of the portal vein (the major vein passing through the liver) and the amount of liver fibrosis in patients with chronic liver disease.

Primary Outcome

Both measurements are estimates of portal hypertension (defined as equal to HVPG greater than 10 mmHg).

Interventions

  • DEVICE ARFI ultrasound

Study Locations (2)

Connecticut

  • Yale-New Haven Hospital - New Haven
  • VA Connecticut Healthcare System - West Haven

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2012-07
Est. Completion 2018-09
Phase NA
VA Connecticut Healthcare System

26 total trials

What the finished NCT01644656 record still lists

NCT01644656 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 153-participant average among 9 other Portal Hypertension trials with a reported enrollment target (227% higher).

The record links to 2 conditions, with Portal Hypertension appearing as the primary indexed condition, and to 1 intervention - of which ARFI ultrasound is the first listed.

NCT01644656 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT01644656 about?

NCT01644656 is a clinical study titled "Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)". The aim of this diagnostic study is to evaluate the efficacy of ARFI imaging (a specific type of ultrasound) in assessing the pressure of the portal vein (the major vein passing through the liver) and the amount of liver fibrosis in patients with chronic liver disease.

What is the current status of trial NCT01644656?

This trial is currently completed. It is a NA study. The enrollment target is 500 participants. The study started on 2012-07. Estimated completion is 2018-09.

What conditions does trial NCT01644656 study?

This clinical trial studies the following conditions: Portal Hypertension, Chronic Liver Disease.

What interventions are being tested in trial NCT01644656?

The interventions under investigation include: ARFI ultrasound (DEVICE).

Who is sponsoring clinical trial NCT01644656?

This trial is sponsored by VA Connecticut Healthcare System, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01644656 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Portal Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01644656's enrollment target sits among peer trials

500 2nd of 9 the highest of 9 other Portal Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Portal Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01644656, the US trial registry maintained by the National Library of Medicine. NCT01644656 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.